

# **EVI27 GENE SEQUENCES AND PROTEIN ENCODED THEREBY**

5

## **BACKGROUND OF THE INVENTION**

### **0 Cross-Reference to Related Application**

This non-provisional patent application claims benefit of provisional patent application U.S. Serial Number 60/180,374, filed February 4, 2000, now abandoned.

### **15 Federal Funding Legend**

This invention was produced in part using funds obtained through a grant from the National Cancer Institute. Consequently, the federal government has certain rights in this invention.

20

Field of the Invention

The present invention relates generally to the field of molecular biology. More specifically, the present invention relates to the cloning and characterization of a murine and human gene 5 that encodes a novel protein with homology to the IL-17 receptor.

Description of the Related Art

Retroviral insertional mutagenesis in BXH2 and AKXD recombinant inbred (RI) mice induces a high incidence of myeloid leukemia and the proviral integration sites in the leukemias provide powerful genetic tags for disease gene identification (Bedigian et al., 1984; Gilbert et al., 1993). During the past several years, a number of disease genes have been identified in these leukemias by proviral tagging. These disease genes include a tumor suppressor gene, 15 *neurofibromatosis type 1 (Nf1)*; a gene with homology to the lymphoid-restricted type II membrane protein Jaw1, *Mrv integration site 1 (Mrvil1)*; a gene encoding a hematopoietic cell growth and differentiation factor, *myeloblastosis oncogene (Myb)*; three homeobox genes, *homeobox A7 (Hoxa7)*, *homeobox A9 (Hoxa9)*, 20 and *myeloid ecotropic viral integration site 1 (Meis1)*; a zinc-finger

protein (*Evi1*); and a gene with homology to the *ubiquitin-specific protease 8* (*Usp8*) oncogene and to genes encoding various cell cycle regulatory proteins, *ecotropic viral integration site 5* (*Evi5*) (Buchberg et al., 1990, Viskochil et al., 1990, Shaughnessy et al., 5 1999; Copeland and Jenkins, 1999, Nakamura et al., 1996a, Morishita et al., 1988, Liao, et al., 1997). Four of the genes are proven or suspected human disease genes: *EVI1*, *NFI* and *HOXA9* are causally associated with myeloid leukemia and *EVI5* with stage 10 4S neuroblastoma (Ogawa et al., 1996, Copeland and Jenkins, 1999, Nakamura et al., 1996b, Roberts et al. 1998), validating the usefulness of this approach for human disease gene identification.

Although proviral tagging has identified many disease genes, it is apparent that several more genes remain to be cloned. This is suggested by the fact only 45% of BXH2 leukemias contain a 15 virally induced mutation in one of the genes identified so far. Disease genes for 55% of BXH2 leukemias remain to be identified. The same is true for human acute myeloid leukemias (AMLS) where the 11 different chromosomal translocations and inversions cloned to date are found in only 45% of acute myeloid leukemias (Look, 20 1997). Disease genes for 55% of acute myeloid leukemias remain to

be identified. Ultimately, it should be possible to use proviral tagging to do a saturation screen for BXH2 disease genes. The expectation is that some of these genes will represent human acute myeloid leukemias genes that are not easy to clone because they are 5 infrequently involved in human disease or are not marked by a cytologically detectable rearrangement. Given the large number of genes that may remain to be identified, this task could be difficult using conventional proviral tagging approaches, which rely on cloning leukemia-specific proviral integration sites into 10 bacteriophage lambda.

With this potential problem in mind, an inverse PCR (IPCR) method for proviral tagging was developed that makes use of automated DNA sequencing and the genetic tools provided by the Mouse Genome Project, which greatly increases the throughput of 15 proviral tagging for disease gene identification. More than 400 proviral integration sites from BXH2 myeloid leukemias (and AKXD T- and B-cell leukemias) were cloned and characterized using this inverse PCR method (Li et al., 1999), which lead to the identification of more than 90 new candidate leukemia disease genes (Li et al., 20 1999). Nineteen new common integration sites (sites that are

targets of viral integration in more than one leukemia) were also identified in these studies and BLAST search and/or chromosome mapping identified candidate disease genes for 12 of these common sites (Li et al., 1999).

5 One common integration site identified by the inverse PCR is *Evi27* (Li et al., 1999). While BLAST searches did not identify a candidate disease gene for *Evi27*, chromosome mapping studies showed that *Evi27* maps to mouse chromosome 14 in a region of human 3p21 homology (Copeland et al., 1993). This result is 10 interesting because treatment-related 3p21 breaks are often observed in myelodysplastic syndrome (MDS) and AML patients (Shi et al., 1996) and 3p21 is the most frequently deleted region seen in chronic myeloid leukemia (CML) (Johansson et al., 1997). *Evi27* may be, therefore, an important human disease gene.

15 The prior art is deficient in lack of the characterization a novel cytokine receptor-related gene whose expression is upregulated by viral integration at *Evi27*. The present invention fulfills this long-standing need and desire in the art.

## SUMMARY OF THE INVENTION

The present invention describes the cloning and sequences of a novel IL-17 receptor-related gene in human and mouse whose expression is upregulated by viral integration in a murine acute myeloid leukemia. Gene transcription and protein expression were examined by northern blot analysis, western blot analysis and immunohistochemical staining. The gene disclosed herein may facilitate myeloid cell transformation and be involved in human disease.

## BRIEF DESCRIPTION OF THE DRAWINGS

15 The appended drawings have been included herein so that the above-recited features, advantages and objects of the invention will become clear and can be understood in detail. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred

embodiments of the invention and should not be considered to limit the scope of the invention.

**Figure 1** shows a partial long-range restriction map of the *Evi27* locus. Bacteriophage  $\lambda$  and P1 clones used for gene localization and exon trapping are shown above the map. The location of the 5' end and transcriptional orientation of the *Evi27* and *Cdh* genes are noted by arrows above the map. The location of the exon with homology to the yeast *ARP8* gene is also noted. The transcriptional orientation of this gene has not been determined. The position and transcriptional orientation of the proviruses in the B160 and 15-38374 leukemias are indicated below the map. The cluster of rare cutting restriction enzymes surrounding the proviral integration sites is also noted. The 14kb *Bam*HI fragment cloned from leukemia B160 is presented below the map. The viral sequences and viral long terminal repeat (LTR) is noted by a thick line and black box, respectively. The position of the 5' end of *Evi27* with respect the viral LTR is noted. Restriction enzymes: B, *Bam*HI; Bs, *Bss*HII; C, *Cl*AI; E, *Eag*I; M, *Mlu*I, N, *Nae*I; Nr, *Nru*I, S, *Sac*II; Sa, *Sal*I;

**Figure 2** shows Northern blot analyses of *Evi27* expression in murine tissues and cancer cell lines. Multiple tissue

Northern blots of normal adult (**Figure 2A**), BXH2 leukemic cell lines (**Figure 2B**), and various hematopoietic cell lines (**Figure 2C**): M1, myeloid leukemia; WEHI3B, monocyte; HYB. 548, B-cell hybridoma; WEHI231, preB-cell lymphoma; R1.1, lymphocytic thymoma; EL4, thymoma, P815, mastocytoma. The blots were also hybridized with a GAPDH or  $\beta$ -actin probe to control for RNA loading. The size in kilobases (kb) of molecular weight markers is show on the left of each panel. To the right of each panel are the sizes of the Evi27 transcripts observed

**Figure 3** shows Northern blot analyses of *EVI27* expression in human tissues and cancer cell lines. Multiple tissue Northern blots of normal adult (**Figure 3A**), immune tissues (**Figure 3B**) and cancer cell lines (**Figure 3C**) hybridized with a n EST specific for the human *EVI27* gene. The human cancer cell lines are HL60, promyelocytic leukemia; HeLa, cervical carcinoma; K562, chronic myelogenous leukemia; MOLT4, T-lymphoblastic leukemia; Raji, Burkitt's lymphoma; SW480, colon adenocarcinoma; A549, lung carcinoma; G361, melanoma. The blots were also hybridized with a  $\beta$ -actin probe to control for RNA loading. The size in kb of molecular weight markers is show on the left of each panel.

Figure 4 shows an alignment of mouse and human *Evi27* proteins. The putative signal peptide, transmembrane domain, and peptide used to generate polyclonal antisera are indicated by a black line over the sequence. Conserved protein motifs are indicated by a double line. Conserved amino acids are boxed with amino acid identities noted in bold. Normal typeface letters represents conservative amino acid changes. Gaps created in the sequences to optimize alignments are indicated by a dash in the sequence string. Abbreviations: N-GLY, N-linked glycosylation; GSK, kinase phosphorylation site.

Figure 5 shows the *Evi27* gene structure. The gene consists of 11 exons with the first and last exons containing untranslated regions. The transmembrane domain is located in exon 10.

Figure 6 shows an alignment of the human EVI27 and IL-17R proteins. Conserved amino acids are boxed with amino acid identities noted in bold. Gaps created in the sequences to optimize alignments are represented by dashes. Amino acid positions are indicated to the right and left of the sequence.

Figure 7 shows the chromosome mapping of the human

EVI27 gene. **Figure 7A** fluorescence *in situ* hybridization of a PAC clone specific for *EVI27 gene* to normal human metaphase chromosomes. Arrows indicate localization of the probe. **Figure 7B** shows G-banding of the same metaphase spread in (**Figure 7A**) following destaining of FISH reagents. The probe is localized to band 3p21.

**Figure 8** shows immunofluorescence and Northern blot analysis of *Evi27* expression in murine cell line. The 2.7 kb cDNA coding for the 55 kD isoform of the membrane bound form of the murine *Evi27* gene was cloned into a eukaryotic expression plasmid vector and transfected into the murine myeloid leukemia cell line 32D. A cell line was established by limiting dilution and called 32DEvi27A. **Figure 8A** shows a Northern blot hybridization of poly-A mRNA from 32D and 32D/Evi27A stable transfectants. Note the abundant expression of the transgene in the transfectant and the absence of expression in the parental line. The blot was also hybridized with a  $\beta$ -actin probe to control for RNA loading. The size in kb of molecular weight markers is show on the left of each panel.

**Figure 8B** shows Western bolt analysis of same cell lines with affinity purified anti-Evi27 antisera. The transfectant shows

overexpression of a 55 kD protein as expected from predicted mRNA translation of the 2.7 kb Evi27 cDNA. Markers in kD are to the left. **Figure 8C** shows immunofluorescence staining of the Evi27 protein (red) in the myeloid cell line 32D (top panel) and 32D 5 cells transfected with an *Evi27* cDNA expression construct (lower panel). Note the light staining in the parental line and abundant staining in the transfectant (left panels). Nuclei are stained blue with DAPI. Cells were also stained with Evi27 antibody preincubated with Evi27 peptide (right panels). Note that no red staining is evident, demonstrating specificity of the antisera. **Figure 8D** shows cell surface expression of Evi27 by flow activated cell sorting analysis (red: anti-Evi27; blue: anti-Evi27+peptide; green: IgG control).

**Figure 9** shows cell surface expression and capping of Evi27 on murine T cell lymphoma EL-4. The left panel shows immunochemistry of the EL-4 cells with the anti-Evi27 antibody before and after pre-treatment with Evi27 peptide. Right panel shows FACs analysis with increasing amount of anti-Evi27 antibody. The capping of Evi27 possibly indicates polydimerization and 15 receptor activation of Evi27. 20

Figure 10 shows subcellular localization of Evi27 in myeloid leukemia B187 and B190. The left panel shows immunochemistry of the B187 and B190 cells with the anti-Evi27 antibody before and after pre-treatment with Evi27 peptide. B187 5 cells show diffuse speckled staining in the cytoplasm, whereas B190 cells shows a capping pattern similar to the EL-4 cells. The signals could be competed away by preincubation with Evi27 peptide. Right panel shows western blot analysis of same cell lines with anti-Evi27. Both cell lines express multiple isoforms of Evi27, and B187 cells express more of the 55 kD isoform. The bands could be competed away by preincubation with Evi27 peptide.

Figure 11 shows abundant Evi27 protein was found in the cytoplasm, but not on the cell surface, in the myeloid leukemia B160. The left panel shows immunochemistry of the B160 cells with 15 the anti-Evi27 antibody before and after pre-treatment with Evi27 peptide. Evi27 is expressed in the cytoplasm at high concentration. Right panel shows FACs analysis with anti-Evi27, indicating Evi27 is not expressed on the cell surface (red: anti-Evi27; black: IgG control).

20 Figure 12 shows Western blot analysis of Evi27 protein

expression in BXH2 leukemia cell lines, EL4 and R1.1 T-cell lines, and the WEHI231 B-cell line. 10  $\mu$ g of protein from cell lysates was run in tandem and hybridized with Evi27 antibody either without (Figure 12A) or with (Figure 12B) preincubation with Evi27 peptide. Note the absence or reduction of specific bands in panel (Figure 12B) compared to (Figure 12A). Molecular weight standards in kD are indicated to the left. The Evi27 isoforms and sizes are indicated to the right of panel A.

Figure 13 shows western blot analysis of Evi27 expression in human cell lines. SW480 and SW620 are colon adenocarcinoma; MEG01, megakaryocytic leukemia; THP-1, monocytic leukemia; K562, chronic myelogenous leukemia; HL-60, promyelocytic leukemia; U266, ARP1 and 8226, multiple myeloma; HeLa, cervical carcinoma; HEL, erythrocytic leukemia. 55 kD and 30 kD are major bands recognized, thus the antibody recognizes both human Evi27 protein isoforms. The bands could be competed away by preincubation of Evi27 antisera with Evi27 peptide as shown in the right panel. MEG01, K562 and HEL cell lines express the highest levels of the Evi27 protein.

Figure 14 shows surface expression of Evi27 on human hematopoietic cell lines. Left panel shows FACS analysis of Evi27 expression on the surface of various human cell lines (red: affinity purified anti-Evi27 antisera; black: IgG control). Evi27 was expressed on THP-1 and K562 cells but not the HL-60 cells. Right panel shows western blot analysis of same cell lines with anti-Evi27. As expected from the FACS data, THP-1 cells express more Evi27 protein than K562 cells, which in turn express more Evi27 than HL-60 cells. It is also shown that K562 cells produce more of the 30 kD soluble form of the Evi27 protein.

10  
10  
10  
10  
10  
10  
10  
10  
10  
10  
10

#### **DETAILED DESCRIPTION OF THE INVENTION**

15

*Evi27* is a common site of retroviral integration in BXH2 murine myeloid leukemias. The present invention shows that integration at *Evi27* occurs in a CpG island ~6 kb upstream from a novel gene (designated *Evi27*) with homology to the *IL17 receptor* (*Il17r*) and that proviral integrations result in increased *Evi27*

expression. The human *EVI27* homologue was also cloned and mapped to chromosome 3p21. Multiple *Evi27* isoforms were detected at the RNA and protein level in both human and mouse, indicating that *Evi27* expression is complex. Some of the isoforms 5 are shown to likely represent secreted soluble forms of the protein produced by intron incorporation or by proteolytic cleavage. In the mouse, highest *Evi27* expression occurs in liver and testes with lower expression in kidney and lung. In humans, *EVI27* is expressed at high levels in the kidney, with moderate levels in the liver, brain, and pancreas. Within hematopoietic cells, *Evi27* expression is 10 restricted. Northern and Western analysis showed that *Evi27* is expressed in selected T-cell, B-cell and myeloid cell lines. These results suggest that *Evi27* expression is tightly regulated during hematopoietic differentiation. Collectively, these studies identify a 15 new member of the cytokine receptor family whose increased and uncoordinated expression may lead to myeloid leukemia by altering *Evi27*'s normal ability to control the growth and/or differentiation of hematopoietic cells.

In accordance with the present invention, there may be 20 employed conventional molecular biology, microbiology, and

recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, *e.g.*, Sambrook, Fritsch & Maniatis, "Molecular Cloning: A Laboratory Manual (2nd Ed.)", (1989); "DNA Cloning: A Practical Approach," Volumes I and II 5 (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription and Translation" [B.D. Hames & S.J. Higgins eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A 10 Practical Guide To Molecular Cloning" (1984). Therefore, if appearing herein, the following terms shall have the definitions set out below.

A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its 15 either single stranded form or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (*e.g.*, restriction fragments), viruses, plasmids, and 20 chromosomes. DNA structures are discussed herein according to

the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (*i.e.*, the strand having a sequence homologous to the mRNA). The term "peptide" or "polypeptide" is defined as several (*i.e.*, multiple) amino acids attached together.

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. A "replicon" is any genetic element (*e.g.*, plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*; *i.e.*, capable of replication under its own control. An "origin of replication" refers to those DNA sequences that participate in or direct DNA synthesis. An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "operably linked" and "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

In general, expression vectors containing promoter

sequences which facilitate the efficient transcription and translation of the inserted DNA fragment are used in connection with a particular host. The expression vector typically contains an origin of replication, promoter(s), terminator(s), as well as specific genes 5 which are capable of providing phenotypic selection in transformed cells (*i.e.*, selectable markers). The transformed hosts can be fermented and cultured according to means known in the art to achieve optimal cell growth.

A DNA "coding sequence" is a double-stranded DNA 10 sequence which is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. Specifically as used herein, "DNA coding for a protein" means DNA sequences which produce a particular primary amino acid sequence. The boundaries of the coding sequence are 15 determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, a cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (*e.g.*, mammalian) organisms and even synthetic DNA 20 sequences. A polyadenylation signal and transcription termination

sequence will usually be located 3' of the coding sequence. A "cDNA" is defined as copy DNA or complementary DNA and is a product of a reverse transcription reaction from an mRNA transcript. An "exon" is an expressed sequence transcribed from 5 the gene locus, whereas an "intron" is a non-expressed sequence that is from the gene locus.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for 10 the expression of a coding sequence in a host cell. A "cis-element" is a nucleotide sequence, also termed a "consensus sequence" or "motif", that interacts with proteins that upregulate or downregulate expression of a specific gene locus. A "signal sequence" can also be included with the coding sequence. This sequence encodes a signal 15 peptide, N-terminal to the polypeptide, that communicates to the host cell and directs the polypeptide to the appropriate cellular location. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.

A "promoter sequence" is a DNA regulatory region 20 capable of binding RNA polymerase in a cell and initiating

transcription of a downstream (3' direction) coding sequence.

Specifically as used herein, the term "promoter(s)" means regulatory DNA sequences that control transcription of the cDNA.

For purposes of defining the present invention, a minimal promoter

5 sequence is bounded at its 3' terminus by the transcription initiation

site and extends upstream (5' direction) to include the minimum

number of bases or elements necessary to initiate transcription at

levels detectable above background. Within the promoter sequence

will be found a transcription initiation site, as well as protein

10 binding domains (consensus sequences) responsible for the binding

of RNA polymerase. Eukaryotic promoters often, but not always,

contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters

contain the -10 and -35 consensus sequences, and additionally,

ribosomal binding Shine-Dalgarno sequences. As used herein,

15 "promoter" may also refer to an intact regulatory sequence

directing transcription (and subsequent translation) of a coding

sequence, and may include any or all of the above-mentioned

transcriptional and translational control sequences.

The term "oligonucleotide" is defined as a molecule

20 comprised of two or more deoxyribonucleotides, preferably more

than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide. The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of 5 acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, *i.e.*, in the presence of nucleotides and a polymerizing agent, such as a DNA polymerase, and at a suitable temperature and pH. The primer may 10 be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the polymerizing agent. The exact length of the primer will depend upon many factors, including 15 temperature, source of primer and use the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.

“Recombinant DNA technology” refers to techniques for 20 uniting two heterologous DNA molecules, usually as a result of *in*

*vitro* ligation of DNAs from different organisms. Recombinant DNA molecules are commonly produced by experiments in genetic engineering. Synonymous terms include "gene splicing", "molecular cloning" and "genetic engineering". The product of these 5 manipulations results in a "recombinant" or "recombinant molecule".

A cell has been "transformed" or "transfected" with exogenous or heterologous DNA when such DNA has been introduced into the cell. Specifically as used herein, the term 10 "transformation" or "transfection" means incorporation permitting expression of heterologous DNA sequences by a cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells, the transforming DNA may be maintained on an episomal 15 element such as a vector or plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell 20 lines or clones comprised of a population of daughter cells

containing the transforming DNA. A "clone" is a population of cells derived from a single cell or ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations. An organism, such as a plant or animal, that has 5 been transformed with exogenous DNA is termed "transgenic".

As used herein, the term "host" is meant to include not only prokaryotes, but also eukaryotes such as yeast, plant and animal cells. Specifically as used herein, the term "host(s)" means any cell that will allow or direct expression. Specifically as used 10 herein, "chimeric cell" means a cell whose DNA has been altered compared to a normal cell of the same organism. A recombinant DNA molecule or gene can be used to transform a host using any of the techniques commonly known to those of ordinary skill in the art. Prokaryotic hosts may include *E. coli*, *S. typhimurium*, 15 *Serratia marcescens* and *Bacillus subtilis*. Eukaryotic hosts include yeasts such as *Pichia pastoris*, mammalian cells and insect cells, and plant cells, such as *Arabidopsis thaliana* and *Tobaccum nicotiana*.

As used herein, "fragment," as applied to a polypeptide, will ordinarily be at least 10 amino acid residues, more typically at 20 least 20 residues, and preferably at least 30 (e.g., 50) residues in

length, but less than the entire, intact sequence. Fragments can be generated by methods known to those skilled in the art, *e.g.*, by enzymatic digestion of naturally occurring or recombinant protein, by recombinant DNA techniques using an expression vector that encodes a defined fragment, or by chemical synthesis. Purified fragments or antigenic fragments can be used to generate antibodies employing standard protocols known to those skilled in the art. As used herein, "functional fragment" is meant to encompass those peptide fragments retaining biological activity of Evi27.

10 Due to the redundancy of the DNA code, there are millions of DNA sequences that would produce the same amino acid sequence when expressed. Given an amino acid sequence, one can substitute into the natural DNA sequence alternative codons for the desired amino acids to produce an alternative DNA sequence also 15 coding for the novel protein. One may find that particular chimeric cells of a particular expression method favor particular mRNA codons for a particular amino acid. Altering the human DNA sequence to increase the frequency of favored codons may improve the expression efficacy in a chimeric cell, thus improving the 20 efficacy of the expression process. The sequences may be derived

by substitution of redundant codons for the amino acid sequences and splicing the substituted sequences into the natural gene by routine methods well known in the art. Those skilled in the art will recognize that many variations are possible in substituting 5 conserved amino acids in the protein sequence which will produce variations in sequence without seriously changing the biological activity of the protein. It is impractical to attempt to list all the millions of DNA sequences that may code for the claimed sequence. However, the invention comprises the novel protein, its novel amino 10 acid sequence, and all DNA sequences natural or synthetic coding for the novel amino acid sequence.

These substitution analogs may be constructed in the following manner: Table 1 lists the alternative codons that code for the 20 common amino acids. DNA sequence substitution analogs 15 that also code for human can be constructed by choosing alternate codons from Table 1 to alter the DNA sequence between a pair of restriction enzyme cleavage sites, as are well known in the art. Alternative codons are assembled into a synthetic oligonucleotide by conventional methods and the synthetic oligo is substituted into the 20 endonuclease treated DNA by the methods described in "Molecular

Cloning. A Laboratory Manual", 2d Edition, Cold Spring Harbor Laboratory Press (1989), to produce a substitution analog. Other methods generally known to those skilled in the art can also be employed to obtain substitution analogs of DNA sequences.

5                   The alteration of the DNA by cleavage and codon substitution may be repeated to substitute substantial portions of the original DNA sequence with alternative codons without altering the protein amino acid sequence. Alteration of a DNA sequence which produces no change in the protein expressed by the DNA 10 sequence might, for example, be conducted to increase protein expression in a particular host cell by increasing the occurrence of codons that correspond to amino acid tRNAs found in higher concentration in the host cell. Such altered DNA sequences for substitution analogs can be easily produced by those of ordinary 15 skill in the art following the method set out above, or other alternative techniques for altering the DNA sequence while obtaining the same protein on expression. Substitution analogs can be obtained by substitution of oligonucleotides at restriction cleavage sites as described above, or by other equivalent methods that 20 change the codons while preserving the amino acid sequence of the

expressed protein.

**TABLE 1**

		<u>SYMBOL</u>	<u>AMINO ACID</u>	<u>CODON USAGE</u>
5		<u>1-Letter</u>	<u>3-Letter</u>	
		A	Ala	Alanine
		C	Cys	Cysteine
		D	Asp	Aspartic acid
		E	Glu	Glutamic acid
10		F	Phe	Phenylalanine
		G	Gly	Glycine
		H	His	Histidine
		I	Ile	Isoleucine
		K	Lys	Lysine
15		L	Leu	Leucine
	CTG			TTA, TTG, CTT, CTC, CTA,
	M	Met	Methionine	ATG
	N	Asn	Asparagine	AAT, AAC
	P	Pro	Proline	CCT, CCC, CCA, CCG
20	Q	Gln	Glutamine	CAA, CAG
	R	Arg	Arginine	CGT, CGC, CGA, CGG, AGA,
	AGG			
	S	Ser	Serine	TCT, TCC, TCA, TCG, AGT,
	AGC			
25	T	Thr	Threonine	ACT, ACC, ACA, ACG
	V	Val	Valine	GTT, GTC, GTG, GTG
	W	Trp	Tryptophan	TTG
	Y	Tyr	Tyrosine	TAT, TAC

30

As described herein, a standard Northern blot assay can be used to ascertain the relative amounts of mRNA in a cell or tissue in accordance with conventional Northern hybridization techniques

known to those persons of ordinary skill in the art. Alternatively, a standard Southern blot assay may be used to confirm the presence, the copy number and/or the position of a gene in accordance with conventional Southern hybridization techniques known to those of ordinary skill in the art. Both the Northern blot and Southern blot use a hybridization probe, (e.g., radiolabelled full-length or partial cDNA) of at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100) consecutive nucleotides in length. The DNA hybridization probe can be labelled by any of the many different methods known to those skilled in this art.

The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA Blue and Lucifer Yellow. Proteins can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$ .

Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques.

The enzyme is conjugated to the selected particle by reaction with  
5 bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase,  $\beta$ -glucuronidase,  $\beta$ -D-glucosidase,  $\beta$ -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase.  
10 U.S. Patent Nos. 3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.

The present invention is directed to an isolated nucleic acid molecule encoding an IL-17 receptor-related protein selected  
15 from the group consisting of: (a) an isolated nucleic acid molecule of SEQ. ID NO: 1, 2, 3 or 4 which encodes an IL-17 receptor-related protein; (b) an isolated nucleic acid molecule which is complimentary and hybridizes to the nucleic acid molecules of (a); and (c) isolated nucleic acid molecule differing from the isolated  
20 nucleic acid molecules of (a) or (b) in codon sequence due to the

degeneracy of the genetic code, and which encodes an IL-17 receptor-related protein.

In one embodiment, there is provided a fragment of one of the nucleic acid molecules listed above that is at least 10 bases 5 long and which will selectively hybridize to nucleic acid molecule encoding an IL-17 receptor-related protein. Preferably, the nucleic acid molecule may be used as an anti-sense molecule to inhibit the expression of an IL-17 receptor-related protein, for chromosomal mapping or mutation analysis of gene encoding an IL-17 receptor-related protein.

The present invention is also directed to a genomic DNA encoding an IL-17 receptor-related protein, wherein said genomic DNA hybridizes to the nucleic acid molecules described above.

The present invention is also directed to vector 15 comprising a nucleic acid molecule of SEQ. ID NO: 1, 2, 3 or 4 and cells transfected with the vector. Representative cells include bacterial cells, mammalian cells, plant cells and insect cells.

The present invention is also directed to an IL-17 receptor-related protein, or a peptide derived thereof, encoded by 20 nucleic acid molecule of SEQ ID No. 3 or 4, wherein said protein is

about 24, 33, 56, 47, 75, 127, and 150 kD in size as detected by western blot analysis in BXH2 leukemia cell. The present invention is further directed to an IL-17 receptor-related protein, or a peptide derived thereof, encoded by the nucleic acid molecules disclosed 5 herein, wherein said protein has the amino acid sequence of SEQ. ID NO: 5, 6, 7 or 8. Preferably, the peptide is at least 4 amino acids long. The peptides can be used to generate anti-Evi27 antibody, and a person having ordinary skill in the art would be readily able to prepare an antibody that binds specifically to any of these proteins 10 or peptides.

The present invention is also directed to a method of stimulating the secretion of cytokines from a cell, comprising the step of binding a ligand to the IL-17 receptor-related protein, Evi27. In general, Evi27 stimulation can lead to the secretion of IL-1, IL-8 15 and TNF- $\alpha$  from hematopoietic cells, leukemia cells and kidney cells.

The present invention is also directed to a method of modulating the expression and activity of an IL-17 receptor-related protein, Evi27, comprising the step of contacting a molecule to a cell, wherein the binding of said molecule to Evi27 mRNA or protein 20 results in increased or decreased expression and activity of the

Evi27 protein. Preferably, the molecule can be anti-sense oligonucleotides, small molecule that binds to Evi27, modified IL-17E or soluble form of the Evi27 receptor.

The following examples are given for the purpose of  
5 illustrating various embodiments of the invention and are not meant  
to limit the present invention in any fashion:

### **EXAMPLE 1**

#### **BXH2 Mice and Leukemic Cell Lines**

The BXH2 recombinant inbred strain was obtained from the Jackson Laboratory (Bar Harbor, ME) and maintained at the NCI-Frederick Cancer Research and Development Center. BXH2 leukemia cell lines have been previously described (Largaespada et al., 1995).

Other cell lines were purchased from the ATCC and grown in either RPMI 1640 or DMEM supplemented with 2mM glutamine, 4.5 g/L glucose, Pen-Strep, and 10% fetal bovine serum (Atlanta Biologicals, Atlanta GA).

## **EXAMPLE 2**

### DNA Extraction and Southern Blot Hybridization

High molecular weight genomic DNAs were extracted  
5 from frozen normal tissues and leukemic spleens and lymph nodes  
as previously described (Jenkins et al., 1982). Bacteriophage and  
plasmid DNAs were purified using standard procedures (Sambrook  
et al., 1987). Restriction enzyme digestions, agarose gel  
electrophoresis, Southern blot transfers, hybridizations, and washes  
10 were performed as previously described (Sambrook et al., 1987).

## **EXAMPLE 3**

### Genomic Cloning

15 70 µg of DNA from leukemia N57 was digested to  
completion with *Bam*HI and fractionated by electrophoresis in TAE  
buffer. Fragments approximating the somatically acquired pAKV5  
(ecotropic murine leukemia virus) hybridizing fragments were cut  
from the gel and purified using Qiaex beads according to the  
20 manufacturer's instructions (Qiagen, Valencia, CA). The *Bam*HI

fragments were cloned into EMBL4 phage arms (Stratagene, La Jolla, CA). Ligated material was packaged with Gigapack Gold packaging extracts (Stratagene, La Jolla, CA). Library screening was performed according to the protocol of Benton and Davis (1977). The P1 and 5 lambda genomic clones were derived from commercial libraries (Genome Systems, St. Louis, MO, Clontech, Palo Alto, CA).

#### **EXAMPLE 4**

##### **10 Human Chromosome Mapping**

Metaphase chromosomes from normal peripheral blood samples were prepared using conventional methods. Slides were incubated in 2XSSC (pH 7.0, 37°C) for 15 minutes then immersed in 0.1N HCl/0.05% Triton X-100 for 15 minutes at room temperature 15 (RT). Slides were washed in 2XSSC (pH 7.0) twice at room temperature, then washed in 1XPBS, pH 7.2 once at room temperature. Slides were immersed in 1% formaldehyde (diluted in PBS) for 10 minutes at room temperature, washed twice in 1XPBS at room temperature, then once in 2XSSC (pH 7.0) at room 20 temperature. Chromosomes were dehydrated in an ethanol series

and air dried at room temperature.

A human PAC clone specific for *EVI27* was isolated by screening a human P1 artificial chromosome (PAC) library according to the manufacturer's instructions and high molecular weight PAC 5 DNA was isolated using the KB-100 kit (Genome Systems, St. Louis, MO). Spectrum-Red-dUTP (Vysis, Downer's Grove, IL) was incorporated into PAC/BAC probes by nick translation according to the manufacturer's protocol (Vysis, Downer's Grove, IL). DNA was resuspended in Hybrisol VII (Oncor, Gaithersburg, MD) (50% 10 formamide/2xSSC) at a final concentration of 5 ng/ul and hybridized to chromosomes according to manufacturer's instructions. The chromosomes and probe solution was incubated at 75°C for 10 minutes. then to 37°C for 16 hrs in a humidified chamber. Post hybridization washes consisted of 65% formamide 15 /2xSSC (pH 7.0) for 15 minutes at 43°C, then 2XSSC (pH 7.0) for 8 minutes at 37°C, 1XPBD (Oncor, Gaithersburg MD) twice at room temperature, then in 1XPBS (pH 7.2). Finally, 10 µl of propidium iodide/antifade (1:20) was added on each area and a coverslip 20 added. Following FISH, the slide was washed twice in Xylene to remove the coverslip and excess oil. The slide was then washed in

1XPBD at 37°C for 5 minutes followed by a dehydration step through an ethanol series. The slide was then incubated in 50% formamide/2XSSC for 90 minutes at 37°C, washed briefly in tap water, followed by dehydration in 10, 80, and 95% ethanol and 5 stained with Wright's stain/phosphate buffer for 5 minutes.

### **EXAMPLE 5**

#### Exon Trapping

10 The P1 clone p57P1 was digested to completion with *Bgl*II and *Bam*HI and purified by phenol extractions and ethanol precipitations. Insert DNA was then ligated to a *Bam*HI digested pSPL3 vector (Life Technologies, Gaithersburg, MD). DNA from the ligations was used to transform DH10B maximum efficiency cells 15 (Life Technologies, Gaithersburg, MD). Additional steps in the experiment were performed exactly according to the manufacuters protocol (Life Technologies). DNA sequence of approximately 100 individual clones from each ligation was generated as described below.

## **EXAMPLE 6**

### Poly(A)+ RNA Isolation and Northern Blot Analysis

Premade Northern blots containing 2  $\mu$ g of twice selected poly(A)+ RNA from various normal tissues and cell lines were purchased from commercial source (CLONTECH, Palo Alto, CA). Total RNA was extracted from cell line suspensions by the RNazol B method (Tel-Test, Friendswood, TX). poly(A)+ RNA was purified from the total RNA preps by oligo-d(T) column chromatography according the manufacturers recommendations (Amersham Pharmacia Biotech, Piscataway, NJ). 2-5  $\mu$ g of poly(A)+ RNA was fractionated by electrophoresis in 1.0 % agarose gels containing formaldehyde and transferred to Hybond N+ membranes (Amersham Pharmacia Biotech, Piscataway, NJ). The membranes were prehybridized and hybridized according to the method of Church and Gilbert or using ExpressHyb solution (Clontech, Palo Alto, CA). Blots were then exposed to X-ray film at -70°C with an intensifying screen.

## **EXAMPLE 7**

### **cDNA Cloning**

cDNA cloning was carried out by a combination of 5' and 3' rapid amplification of cDNA ends (5' and 3' RACE) and modified 5 RT-PCR as described (Shaughnessy et al., 1999). Briefly, the nucleotide sequence of the trapped exon p57P1ET47 was used to 10 design specific nested oligonucleotides. The primary 5' and 3' RACE reactions were performed using mouse liver Marathon Ready cDNA (Clontech, Palo Alto, CA) as a template according to the manufacturer's protocol using the Advantage cDNA amplification kit 15 (Clontech, Palo Alto, CA). After cloning and sequencing, nested primers specific for the 5' and 3' ends of the gene were synthesized. Another cycle of PCR was performed using Marathon Ready liver cDNA as a template and the full length cDNA was generated by PCR as follows: 1 cycle: 94°C 1min; 30 cycles: 94°C, 30 sec, 68°C, 7 min. The products of the reaction were subcloned into pCR2.1 (Invitrogen, Carlsbad, CA) and sequenced. The full-length cDNA of the 1.9 kb and 2.7 kb transcripts have been submitted to GenBank under accession numbers AF208108 and AF208109, respectively.

Human cDNAs covering the coding region of the *EVI27* gene were synthesized in a similar manner as described above. Briefly, a human EST (accession number T96740), with high homology to the mouse *EVI27* cDNA, was used to design nested 5 oligonucleotide primers at the 5' and 3' end of the EST. 5' and 3' RACE products from Marathon Ready fetal liver cDNA (Clontech, Palo Alto, CA) were synthesized as described above. The 1.9 kb and 2.9 kb human *EVI27* cDNA nucleotide sequences are deposited in GenBank under accession numbers AF208110 and AF208111.

10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000  
1005  
1010  
1015  
1020  
1025  
1030  
1035  
1040  
1045  
1050  
1055  
1060  
1065  
1070  
1075  
1080  
1085  
1090  
1095  
1100  
1105  
1110  
1115  
1120  
1125  
1130  
1135  
1140  
1145  
1150  
1155  
1160  
1165  
1170  
1175  
1180  
1185  
1190  
1195  
1200  
1205  
1210  
1215  
1220  
1225  
1230  
1235  
1240  
1245  
1250  
1255  
1260  
1265  
1270  
1275  
1280  
1285  
1290  
1295  
1300  
1305  
1310  
1315  
1320  
1325  
1330  
1335  
1340  
1345  
1350  
1355  
1360  
1365  
1370  
1375  
1380  
1385  
1390  
1395  
1400  
1405  
1410  
1415  
1420  
1425  
1430  
1435  
1440  
1445  
1450  
1455  
1460  
1465  
1470  
1475  
1480  
1485  
1490  
1495  
1500  
1505  
1510  
1515  
1520  
1525  
1530  
1535  
1540  
1545  
1550  
1555  
1560  
1565  
1570  
1575  
1580  
1585  
1590  
1595  
1600  
1605  
1610  
1615  
1620  
1625  
1630  
1635  
1640  
1645  
1650  
1655  
1660  
1665  
1670  
1675  
1680  
1685  
1690  
1695  
1700  
1705  
1710  
1715  
1720  
1725  
1730  
1735  
1740  
1745  
1750  
1755  
1760  
1765  
1770  
1775  
1780  
1785  
1790  
1795  
1800  
1805  
1810  
1815  
1820  
1825  
1830  
1835  
1840  
1845  
1850  
1855  
1860  
1865  
1870  
1875  
1880  
1885  
1890  
1895  
1900  
1905  
1910  
1915  
1920  
1925  
1930  
1935  
1940  
1945  
1950  
1955  
1960  
1965  
1970  
1975  
1980  
1985  
1990  
1995  
2000  
2005  
2010  
2015  
2020  
2025  
2030  
2035  
2040  
2045  
2050  
2055  
2060  
2065  
2070  
2075  
2080  
2085  
2090  
2095  
2100  
2105  
2110  
2115  
2120  
2125  
2130  
2135  
2140  
2145  
2150  
2155  
2160  
2165  
2170  
2175  
2180  
2185  
2190  
2195  
2200  
2205  
2210  
2215  
2220  
2225  
2230  
2235  
2240  
2245  
2250  
2255  
2260  
2265  
2270  
2275  
2280  
2285  
2290  
2295  
2300  
2305  
2310  
2315  
2320  
2325  
2330  
2335  
2340  
2345  
2350  
2355  
2360  
2365  
2370  
2375  
2380  
2385  
2390  
2395  
2400  
2405  
2410  
2415  
2420  
2425  
2430  
2435  
2440  
2445  
2450  
2455  
2460  
2465  
2470  
2475  
2480  
2485  
2490  
2495  
2500  
2505  
2510  
2515  
2520  
2525  
2530  
2535  
2540  
2545  
2550  
2555  
2560  
2565  
2570  
2575  
2580  
2585  
2590  
2595  
2600  
2605  
2610  
2615  
2620  
2625  
2630  
2635  
2640  
2645  
2650  
2655  
2660  
2665  
2670  
2675  
2680  
2685  
2690  
2695  
2700  
2705  
2710  
2715  
2720  
2725  
2730  
2735  
2740  
2745  
2750  
2755  
2760  
2765  
2770  
2775  
2780  
2785  
2790  
2795  
2800  
2805  
2810  
2815  
2820  
2825  
2830  
2835  
2840  
2845  
2850  
2855  
2860  
2865  
2870  
2875  
2880  
2885  
2890  
2895  
2900  
2905  
2910  
2915  
2920  
2925  
2930  
2935  
2940  
2945  
2950  
2955  
2960  
2965  
2970  
2975  
2980  
2985  
2990  
2995  
3000  
3005  
3010  
3015  
3020  
3025  
3030  
3035  
3040  
3045  
3050  
3055  
3060  
3065  
3070  
3075  
3080  
3085  
3090  
3095  
3100  
3105  
3110  
3115  
3120  
3125  
3130  
3135  
3140  
3145  
3150  
3155  
3160  
3165  
3170  
3175  
3180  
3185  
3190  
3195  
3200  
3205  
3210  
3215  
3220  
3225  
3230  
3235  
3240  
3245  
3250  
3255  
3260  
3265  
3270  
3275  
3280  
3285  
3290  
3295  
3300  
3305  
3310  
3315  
3320  
3325  
3330  
3335  
3340  
3345  
3350  
3355  
3360  
3365  
3370  
3375  
3380  
3385  
3390  
3395  
3400  
3405  
3410  
3415  
3420  
3425  
3430  
3435  
3440  
3445  
3450  
3455  
3460  
3465  
3470  
3475  
3480  
3485  
3490  
3495  
3500  
3505  
3510  
3515  
3520  
3525  
3530  
3535  
3540  
3545  
3550  
3555  
3560  
3565  
3570  
3575  
3580  
3585  
3590  
3595  
3600  
3605  
3610  
3615  
3620  
3625  
3630  
3635  
3640  
3645  
3650  
3655  
3660  
3665  
3670  
3675  
3680  
3685  
3690  
3695  
3700  
3705  
3710  
3715  
3720  
3725  
3730  
3735  
3740  
3745  
3750  
3755  
3760  
3765  
3770  
3775  
3780  
3785  
3790  
3795  
3800  
3805  
3810  
3815  
3820  
3825  
3830  
3835  
3840  
3845  
3850  
3855  
3860  
3865  
3870  
3875  
3880  
3885  
3890  
3895  
3900  
3905  
3910  
3915  
3920  
3925  
3930  
3935  
3940  
3945  
3950  
3955  
3960  
3965  
3970  
3975  
3980  
3985  
3990  
3995  
4000  
4005  
4010  
4015  
4020  
4025  
4030  
4035  
4040  
4045  
4050  
4055  
4060  
4065  
4070  
4075  
4080  
4085  
4090  
4095  
4100  
4105  
4110  
4115  
4120  
4125  
4130  
4135  
4140  
4145  
4150  
4155  
4160  
4165  
4170  
4175  
4180  
4185  
4190  
4195  
4200  
4205  
4210  
4215  
4220  
4225  
4230  
4235  
4240  
4245  
4250  
4255  
4260  
4265  
4270  
4275  
4280  
4285  
4290  
4295  
4300  
4305  
4310  
4315  
4320  
4325  
4330  
4335  
4340  
4345  
4350  
4355  
4360  
4365  
4370  
4375  
4380  
4385  
4390  
4395  
4400  
4405  
4410  
4415  
4420  
4425  
4430  
4435  
4440  
4445  
4450  
4455  
4460  
4465  
4470  
4475  
4480  
4485  
4490  
4495  
4500  
4505  
4510  
4515  
4520  
4525  
4530  
4535  
4540  
4545  
4550  
4555  
4560  
4565  
4570  
4575  
4580  
4585  
4590  
4595  
4600  
4605  
4610  
4615  
4620  
4625  
4630  
4635  
4640  
4645  
4650  
4655  
4660  
4665  
4670  
4675  
4680  
4685  
4690  
4695  
4700  
4705  
4710  
4715  
4720  
4725  
4730  
4735  
4740  
4745  
4750  
4755  
4760  
4765  
4770  
4775  
4780  
4785  
4790  
4795  
4800  
4805  
4810  
4815  
4820  
4825  
4830  
4835  
4840  
4845  
4850  
4855  
4860  
4865  
4870  
4875  
4880  
4885  
4890  
4895  
4900  
4905  
4910  
4915  
4920  
4925  
4930  
4935  
4940  
4945  
4950  
4955  
4960  
4965  
4970  
4975  
4980  
4985  
4990  
4995  
5000  
5005  
5010  
5015  
5020  
5025  
5030  
5035  
5040  
5045  
5050  
5055  
5060  
5065  
5070  
5075  
5080  
5085  
5090  
5095  
5100  
5105  
5110  
5115  
5120  
5125  
5130  
5135  
5140  
5145  
5150  
5155  
5160  
5165  
5170  
5175  
5180  
5185  
5190  
5195  
5200  
5205  
5210  
5215  
5220  
5225  
5230  
5235  
5240  
5245  
5250  
5255  
5260  
5265  
5270  
5275  
5280  
5285  
5290  
5295  
5300  
5305  
5310  
5315  
5320  
5325  
5330  
5335  
5340  
5345  
5350  
5355  
5360  
5365  
5370  
5375  
5380  
5385  
5390  
5395  
5400  
5405  
5410  
5415  
5420  
5425  
5430  
5435  
5440  
5445  
5450  
5455  
5460  
5465  
5470  
5475  
5480  
5485  
5490  
5495  
5500  
5505  
5510  
5515  
5520  
5525  
5530  
5535  
5540  
5545  
5550  
5555  
5560  
5565  
5570  
5575  
5580  
5585  
5590  
5595  
5600  
5605  
5610  
5615  
5620  
5625  
5630  
5635  
5640  
5645  
5650  
5655  
5660  
5665  
5670  
5675  
5680  
5685  
5690  
5695  
5700  
5705  
5710  
5715  
5720  
5725  
5730  
5735  
5740  
5745  
5750  
5755  
5760  
5765  
5770  
5775  
5780  
5785  
5790  
5795  
5800  
5805  
5810  
5815  
5820  
5825  
5830  
5835  
5840  
5845  
5850  
5855  
5860  
5865  
5870  
5875  
5880  
5885  
5890  
5895  
5900  
5905  
5910  
5915  
5920  
5925  
5930  
5935  
5940  
5945  
5950  
5955  
5960  
5965  
5970  
5975  
5980  
5985  
5990  
5995  
6000  
6005  
6010  
6015  
6020  
6025  
6030  
6035  
6040  
6045  
6050  
6055  
6060  
6065  
6070  
6075  
6080  
6085  
6090  
6095  
6100  
6105  
6110  
6115  
6120  
6125  
6130  
6135  
6140  
6145  
6150  
6155  
6160  
6165  
6170  
6175  
6180  
6185  
6190  
6195  
6200  
6205  
6210  
6215  
6220  
6225  
6230  
6235  
6240  
6245  
6250  
6255  
6260  
6265  
6270  
6275  
6280  
6285  
6290  
6295  
6300  
6305  
6310  
6315  
6320  
6325  
6330  
6335  
6340  
6345  
6350  
6355  
6360  
6365  
6370  
6375  
6380  
6385  
6390  
6395  
6400  
6405  
6410  
6415  
6420  
6425  
6430  
6435  
6440  
6445  
6450  
6455  
6460  
6465  
6470  
6475  
6480  
6485  
6490  
6495  
6500  
6505  
6510  
6515  
6520  
6525  
6530  
6535  
6540  
6545  
6550  
6555  
6560  
6565  
6570  
6575  
6580  
6585  
6590  
6595  
6600  
6605  
6610  
6615  
6620  
6625  
6630  
6635  
6640  
6645  
6650  
6655  
6660  
6665  
6670  
6675  
6680  
6685  
6690  
6695  
6700  
6705  
6710  
6715  
6720  
6725  
6730  
6735  
6740  
6745  
6750  
6755  
6760  
6765  
6770  
6775  
6780  
6785  
6790  
6795  
6800  
6805  
6810  
6815  
6820  
6825  
6830  
6835  
6840  
6845  
6850  
6855  
6860  
6865  
6870  
6875  
6880  
6885  
6890  
6895  
6900  
6905  
6910  
6915  
6920  
6925  
6930  
6935  
6940  
6945  
6950  
6955  
6960  
6965  
6970  
6975  
6980  
6985  
6990  
6995  
7000  
7005  
7010  
7015  
7020  
7025  
7030  
7035  
7040  
7045  
7050  
7055  
7060  
7065  
7070  
7075  
7080  
7085  
7090  
7095  
7100  
7105  
7110  
7115  
7120  
7125  
7130  
7135  
7140  
7145  
7150  
7155  
7160  
7165  
7170  
7175  
7180  
7185  
7190  
7195  
7200  
7205  
7210  
7215  
7220  
7225  
7230  
7235  
7240  
7245  
7250  
7255  
7260  
7265  
7270  
7275  
7280  
7285  
7290  
7295  
7300  
7305  
7310  
7315  
7320  
7325  
7330  
7335  
7340  
7345  
7350  
7355  
7360  
7365  
7370  
7375  
7380  
7385  
7390  
7395  
7400  
7405  
7410  
7415  
7420  
7425  
7430  
7435  
7440  
7445  
7450  
7455  
7460  
7465  
7470  
7475  
7480  
7485  
7490  
7495  
7500  
7505  
7510  
7515  
7520  
7525  
7530  
7535  
7540  
7545  
7550  
7555  
7560  
7565  
7570  
7575  
7580  
7585  
7590  
7595  
7600  
7605  
7610  
7615  
7620  
7625  
7630  
7635  
7640  
7645  
7650  
7655  
7660  
7665  
7670  
7675  
7680  
7685  
7690  
7695  
7700  
7705  
7710  
7715  
7720  
7725  
7730  
7735  
7740  
7745  
7750  
7755  
7760  
7765  
7770  
7775  
7780  
7785  
7790  
7795  
7800  
7805  
7810  
7815  
7820  
7825  
7830  
7835  
7840  
7845  
7850  
7855  
7860  
7865  
7870  
7875  
7880  
7885  
7890  
7895  
7900  
7905  
7910  
7915  
7920  
7925  
7930  
7935  
7940  
7945  
7950  
7955  
7960  
7965  
7970  
7975  
7980  
7985  
7990  
7995  
8000  
8005  
8010  
8015  
8020  
8025  
8030  
8035  
8040  
8045  
8050  
8055  
8060  
8065  
8070  
8075  
8080  
8085  
8090  
8095  
8100  
8105  
8110  
8115  
8120  
8125  
8130  
8135  
8140  
8145  
8150  
8155  
8160  
8165  
8170  
8175  
8180  
8185  
8190  
8195  
8200  
8205  
8210  
8215  
8220  
8225  
8230  
8235  
8240  
8245  
8250  
8255  
8260  
8265  
8270  
8275  
8280  
8285  
8290  
8295  
8300  
8305  
8310  
8315  
8320  
8325  
8330  
8335  
8340  
8345  
8350  
8355  
8360  
8365  
8370  
8375  
8380  
8385  
8390  
8395  
8400  
8405  
8410  
8415  
8420  
8425  
8430  
8435  
8440  
8445  
8450  
8455  
8460  
8465  
8470  
8475  
8480  
8485  
8490  
8495  
8500  
8505  
8510  
8515  
8520  
8525  
8530  
8535  
8540  
8545  
8550  
8555  
8560  
8565  
8570  
8575  
8580  
8585  
8590  
8595  
8600  
8605  
8610  
8615  
8620  
8625  
8630  
8635  
8640  
8645  
8650  
8655  
8660  
8665  
8670  
8675  
8680  
8685  
8690  
8695  
8700  
8705  
8710  
8715  
8720  
8725  
8730  
8735  
8740  
8745  
8750  
8755  
8760  
8765  
8770  
8775  
8780  
8785  
8790  
8795  
8800  
8805  
8810  
8815  
8820  
8825  
8830  
8835  
8840  
8845  
8850  
8855  
8860  
8865  
8870  
8875  
8880  
8885  
8890  
8895  
8900  
8905  
8910  
8915  
8920  
8925  
8930  
8935  
8940  
8945  
8950  
8955  
8960  
8965  
8970  
8975  
8980  
8985  
8990  
8995  
9000  
9005  
9010  
9015  
9020  
9025  
9030  
9035  
9040  
9045  
9050  
9055  
9060  
9065  
9070  
9075  
9080  
9085  
9090  
9095  
9100  
9105  
9110  
9115  
9120  
9125  
9130  
9135  
9140  
9145  
9150  
9155  
9160  
9165  
9170  
9175  
9180  
9185  
9190  
9195  
9200  
9205  
9210  
9215  
9220  
9225  
9230  
9235  
9240  
9245  
9250  
9255  
9260  
9265  
9270  
9275  
9280  
9285  
9290  
9295  
9300  
9305  
9310  
9315  
9320  
9325  
9330  
9335  
9340  
9345  
9350  
9355  
9360  
9365  
9370  
9375  
9380  
9385  
9390  
9395  
9400  
9405  
9410  
9415  
9420  
9425  
9430  
9435  
9440  
9445  
9450  
9455  
9460  
9465  
9470  
9475  
9480  
9485

3X in FBS-free DMEM media. Cells were resuspended at  $5 \times 10^6$  cells per ml in FBS-free DMEM. One ml of the cell suspension was mixed with DEAE dextran at 0.1  $\mu$ g/ml and 10  $\mu$ g of plasmid DNA in an 0.4 cm electrode gap electroporation cuvette and chilled on ice for 10 minutes and Eletroporated at 270 V/975  $\mu$ F in a Gene Pulser II (Bio-Rad, Hercules, CA). The cuvette was chilled on ice for 10 minutes then the cells were transferred into 10 ml of fresh media and grown for 72 hrs. G418 selection was carried out in 2 mg/ml for 2 weeks. Limiting dilution cloning in 96 well culture dishes was performed at 1 mg/ml G418 on all cell lines with the exception of NIH3T3. Stable transfectants were cloned and tested for expression of the transgene by Northern blot hybridization.

#### **EXAMPLE 9**

15

#### Southern and Northern Blot Probes

The  $\beta$ -actin probe was a 2.0 kb cDNA (Clontech, Palo Alto, CA). Probes pAKV5 and pEco have been described (Nakamura et al., 1996). p57BXH2A was a 700 bp PCR fragment generated from

the flanking DNA from clone p57BXH2. Probe p57ET47 was a 103 bp exon trapped from p57 P1. The human intron probe was synthesized by PCR from genomic DNA. Human ESTs were derived from IMAGE consortium clones. Full length 1.9 kb human and 5 mouse *Evi27* cDNAs were used in all probes were labeled with [ $\alpha$ <sup>32</sup>P]-dCTP using the Prime It II labeling kit (Stratagene, La Jolla, CA).

#### **EXAMPLE 10**

##### DNA Sequencing

DNA sequencing was performed using the PRISM Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit (Perkin Elmer) on the ABI Model 373A DNA Sequencer (Applied Biosystems). 15 Sequence primers were either the T3, T7 sequencing primers or synthetic oligomers derived from previously determined sequence.

## EXAMPLE 11

### Immunohistochemistry

Cells were harvested and washed once in PBS and  
5 resuspended at 1-2 x 10<sup>6</sup> cells per ml in PBS. 0.5 ml of the cell  
suspension was subjected to cytocentrifugation at 1200 x g for 5-10  
minutes and air dried for 15-20 minutes, rinsed in PBS and drained  
well but not allowed to dry. Slides were fixed in fresh 4%  
10 paraformaldehyde for 10 minutes followed by two washes in PBS.  
Cells were permeabilized by incubation in acetone for 30 seconds at  
RT. Slides were rinsed in PBS with four changes over 5 minutes.  
Cells were blocked with 5% goat serum in PBS for 30 minutes at RT.  
The polyclonal anti-peptide EVI27 antibody, 2954, was affinity  
15 purified using the Sulfa-Link kit according to manufacturer's  
instructions (Pierce, Rockford, IL). Antibodies were diluted in 1 M  
HEPES buffer containing 0.15 N NaCl. Sixty microliters of the  
primary antibody solution was added to slides and incubated for 30  
minutes in a humidified chamber at RT. The primary antibody was  
blocked with 100 µg of peptide by incubating for 1 hour at RT. This  
20 solution was then added to the slides as above. After hybridization

the slides were washed three times for 5 minutes in 1XPBD (Oncor, Gaithersburg, MD). The secondary antibody, a rhodamine conjugated goat-anti-rabbit antibody (Pierce, Rockford, IL) was diluted in the same buffer as the primary antibody and the solution 5 was added to slides for 30 minutes. Slides were washed 3X in PBS for 5 minutes each wash. The nuclei were counterstained with DAPI at 1/40 dilution in antifade (Oncor, Gaithersburg, MD), coverslips added and viewed with an Olympus BX60 epifluorescence microscope.

#### **EXAMPLE 12**

#### **Western Blotting**

Cells were harvested at logarithmic growth stage and 15 washed 2X in 1XPBS. Cells were resuspended in extraction buffer (1x PBS (pH 7.2), 10  $\mu$ g/ml Aprotinin (0.1 unit/ml), 10  $\mu$ g/ml Leupeptin, 1mM PMSF) at  $10^6$  cells/100  $\mu$ l. Protein was extracted by the freeze-thaw method. The solid phase was removed by centrifugation at 12,000g x 10 minutes at 4°C. The aqueous phase

was collected concentrated and quantified using the BCA assay kit (Pierce, Rockford, IL). Protein separating gels were precast (Novex, San Diego, CA). Protein (50-100  $\mu$ g) was mixed 1:1 with sample buffer (2X) (Novex, San Diego, CA), denatured for 15 minutes, 5 cooled to RT and loaded. Gels were run for 2-3 hours at 200V with cooling (60W initially) in 1X running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS at pH 8.3). Protein was transferred to Hybond-C super membrane (Amersham Pharmacia Biotech, Piscataway, NJ) using an electrophoretic blotting system (C.B.S. Scientific Co. Del 10 Mar, CA) in 1X transfer buffer (48mM Tris, 39 mM glycine, 20% methanol) at 100V for 5-6 hrs. The western blot was processed as described (WesternBreeze kit, Novex, San Diego, CA).

15

### **EXAMPLE 13**

#### Computer DNA and Protein Sequence Analysis

Sequence homology searches were conducted at the protein level using the National Center for Biotechnology 20 Information and the BLAST network service. The DNA and protein

sequence alignments and protein motif sequence searches were performed using MacVector (Oxford Molecular Group, Beaverton, OR) and pSORT (Nakai and Kanehisa, 1992).

5

#### **EXAMPLE 14**

#### Cloning and Characterization of Genomic Sequences from the *Evi27* locus

Genomic restriction analysis of DNA from two BXH2 leukemias with proviral integrations at *Evi27* (N57 [B160] and 15-38374) showed that the integrations in the two leukemias are located about 1.5 kb apart and are oriented in the same transcriptional direction (Figure 1). Lambda and P1 clones from the region were then isolated, restriction mapped and exon trapped.

Four exon-trapped products were identified. BLAST searches showed that two of the exons were derived from the mouse choline dehydrogenase (*Chdh*) gene, while one exon was derived from a gene with high homology to the yeast actin-like protein, ARP8 (accession number S67026). The *Chdh* gene was subsequently

positioned ~10 kb to the left of the proviral integration sites and in the opposite transcriptional direction (Figure 1). Northern analysis showed that *Chdh* expression is restricted to liver and is not activated in the B160 cell line (a cell line derived from the N57 5 leukemia that carries a proviral integration at *Evi27*). The *ARP8* homologue was mapped ~15-20 kb to the right of the proviral integration sites. Northern analysis showed that this gene is ubiquitously expressed and is not upregulated in B160 leukemia cells. On this basis, *Chdh* and *ARP8* were excluded as candidate 10 disease genes.

The fourth exon (p57ET47) showed no significant homology to any sequences in GeneBank. Hybridization studies showed that this exon was contained within lambda clone p57λ129 (Figure 1), indicating that it was located within 5-20 kb of the 15 proviral integration sites at *Evi27*. DNA sequence analysis of p57λ129 identified a 103 bp fragment that was homologous to a human fetal liver cDNA EST (accession number T96740). This EST sequence was localized 1240 bp upstream of p57ET47 and was found to be oriented in the same transcriptional direction, 20 suggesting that both exons might be derived from the same gene.

Northern blot analysis of mouse tissues using both exons as probes confirmed this prediction and showed that the *Evi27* hybridization pattern is complex. Six different *Evi27* transcripts of approximately 4.4, 4.2, 2.3, 1.9, 1.3, and 1.1kb in size, could be 5 detected on northern blots (Figure 2). In adult tissues the expression was seen in liver and testes where the 2.3 and 1.9 kb transcripts predominated. Expression of the 4.2 transcript was also seen in liver and testes. In addition, low levels of the 2.3 and 1.9kb transcripts were seen in kidney (Figure 2A). With long exposure, the 10 lung showed expression of a 2.1kb transcript, while the heart showed expression of the 1.3kb transcript. No expression was seen in skeletal muscle, brain, or spleen.

In addition to adult tissues, *Evi27* expression was also detected in some hematopoietic cell lines. These cell lines include 15 the EL-4 T-cell line, which express the 4.2 and 1.3 kb transcripts, the WEHI231 B-cell line which expresses the 4.2, 1.3 and 1.1 kb transcripts, and the R1.1 T-cell line, which expresses the 1.9 kb transcript. In contrast, little or no expression was detected in the 32D, WEHI 3B, and M1 myeloid cell lines, the HYB.548 B-cell line, or 20 the P815 mast cell line (Figure 2C).

5 *Evi27* expression could also be detected in BXH2 myeloid cell lines whether or not they carry a proviral integration at *Evi27*. Expression of the 4.4, 4.2, 1.9 and 1.1kb transcripts was variable among the different lines (Figure 2C), but the highest expression was seen in the B160 cell line, which contains a viral integration at *Evi27*.

In this cell line the 4.4 kb transcript predominated. These results suggest that viral integration at *Evi27* results in increased *Evi27* expression.

10 In humans, two *EVI27* transcripts, 1.9 kb and 2.7 kb in size, were detected (Figure 3). Human *EVI27* expression is therefore considerably less complex than in mouse. The highest *EVI27* expression was seen in kidney (Figure 3A), while in the mouse, *Evi27* was expressed at low levels in the kidney. Moderate expression was also observed in the brain, liver, and testes with low to undetectable 15 expression in lung. No *EVI27* expression was seen in heart, placenta, and skeletal muscle (Figure 3A) or in immune tissues such as spleen, lymph nodes, thymus, peripheral blood lymphocytes, or bone marrow (Figure 3B). High *EVI27* expression was, however, observed in the fetal liver.

20 Within cell lines, moderate *EVI27* expression was seen in

the cervical carcinoma HeLa, chronic myelogenous leukemia, K562, and colon adenocarcinoma, SW480 cell lines (Figure 3C), but not in the myeloid leukemia HL-60, acute lymphoblastic T-cell leukemia MOLT-4, Burkitt's lymphoma Raji, lung carcinoma A549 and the 5 melanoma G361 cell lines.

### **EXAMPLE 15**

10 The Gene Whose Expression is Upregulated by Viral integration at  
Evi27 encodes a Novel IL-17 Receptor-Related Protein

15 The complete coding region of human gene was obtained by 3', and then 5' RACE. The primary 5' RACE product using primers from the 3' end of the gene was ~1.9 kb in length, consistent with the size of the major human transcript. A larger minor species was also produced in the 5' RACE reaction. Sequence analysis showed that it contained an additional 950 bp of sequence that was not present in the 1.9 kb product. PCR and genomic sequence analysis showed that this extra sequence was an unspliced intron. Northern 20 analysis showed that the 2.7 kb human transcript contains this

unspliced intron and sequence analysis showed that this unspliced intron introduces multiple stop codons into the open reading frame of the protein.

The sequence of the full length 1.9 kb and 2.7 kb transcripts has been deposited in GenBank with accession numbers AF208110 and AF208111, respectively; SEQ. ID NO: 1 and SEQ. ID NO: 2 respectively in the present invention. The predicted uninterrupted protein is 502 amino acids (aa) and has a predicted molecular weight of 56 kD (Figure 4). pSORT analysis identified a potential cleavable signal peptide at the N terminus of the protein. A putative transmembrane domain starts at residue 293 and ends at residue 309. The cytoplasmic tail is predicted to extend from residue 310 to the C terminus. pSORT analysis also indicated that the protein has type 1a topology. A string of 39 amino acids derived from intronic sequences would be inserted at amino acid 250 in the 2.7 kb transcript. This would result in the synthesis of a 288 amino acids protein with a predicted molecular weight of 31 kD. The transmembrane and cytoplasmic portions of the 502 amino acids isoform are missing in this truncated form of the protein.

Multiple 5' RACE products were also obtained in mouse.

Cloning and sequence analysis of these RACE products showed that they can be created by the inclusion of at least two unspliced introns. As in human, these intron sequences introduce multiple stop codons into the open reading frame of the protein. The 5 sequence of the full length 1.9 kb and 2.5 kb mouse transcripts has been deposited in GenBank with accession numbers AF208108 and AF208109, respectively; SEQ. ID NO: 3 and SEQ. ID NO: 4 respectively in the present invention. The mouse 4.4, 4.2, 2.4 and 1.3 kb transcripts have not been cloned and sequenced.

10 Genomic sequence analysis indicates that the mouse gene consists of 11 exons and spans ~13 kb of genomic DNA (Figure 5). It is interesting to note that Evi27 cDNAs specifically lacking exon 10 have been cloned from mouse AML cell lines. The gene is transcribed in the same orientation as the integrated proviruses, 15 which lie in a CpG rich region located approximately 6 kb 5' from the first known exon of the gene (Figure 1). The predicted open reading frame of the 1.9 kb transcript is 499 amino acids with a predicted molecular weight of 56 kD (Figure 4). pSORT analysis identified a potential cleavable signal peptide in the N terminus of 20 the protein, just like in the human protein. A putative

transmembrane domain starts at amino acid 290 and ends at amino acid 293. The transmembrane domain is located in exon 12 of the gene and is spliced out in variant transcripts sequenced from the WEHI-231 B-cell line. These variant transcripts splice out an exon 5 containing the entire putative transmembrane domain. The lack of this exon does not disrupt the predicted open reading frame of the protein.

In the 2.5 kb transcript, a string of 57 novel amino acids, derived from intron 7, is added at amino acid 162 creating a protein with an open reading frame of 218 amino acids and a predicted molecular weight of 24 kD. Like the shorter human isoform, this isoform would lack the transmembrane and cytoplasmic domains of the protein.

The full-length human and mouse proteins are 83% similar and 76% identical (Figure 4). The extracellular domain of both proteins contains three conserved N-linked glycosylation and a GSK3 phosphorylation site. A single conserved GSK3 phosphorylation site is also present in the cytoplasmic domain.

Amino acid sequence comparisons showed that *Evi27* has 20 significant homology throughout its coding region to the human and

mouse *IL-17 receptor* (*IL-17R*) (E value = 2.5 e-29) (Figure 6). The position of the transmembrane domain with respect to the amino terminus is essentially the same in the two proteins. However, the cytoplasmic tail of the *IL-17R* is nearly 304 amino acids longer than 5 that of the *Evi27*. Although *Evi27* is predicted to encode both membrane bound and soluble forms, *IL-17R* is not known to encode a soluble form.

#### **EXAMPLE 16**

##### **The Mouse and Human Genes map in Syntenic Regions**

The human *EVI27* gene was mapped to chromosome 3p21 by fluorescence *in situ* hybridization of high-resolution G-banded chromosomes (Figure 7). These results are consistent with 15 the mouse mapping data, which localize the mouse gene to chromosome 14 in a region of human 3p21 homology (Copeland et al., 1995). They also confirm that the human gene maps in a region of the human genome that is frequently rearranged in human 20 myeloid leukemia.

## EXAMPLE 17

### Expression and Subcellular Localization of Evi27

The expression and subcellular localization of the mouse  
5 protein was examined using a polyclonal antibody raised against a  
peptide derived from the C-terminus of Evi27. Antibody specificity  
was confirmed by immunofluorescence staining of 32D cells, which  
express undetectable levels of *Evi27* mRNA (Figure 8A), and 32D  
cells stably transfected with a 2.7 kb *Evi27* cDNA clone. Western  
blot analysis showed that whereas the parental 32D cells show weak  
expression of the expected 55 kD full length protein, the transfected  
line expresses approximately 3-5 fold higher levels of this isoform  
10 (Figure 8B). Immunofluorescence analysis showed weak staining in  
the parental 32D cells whereas the transfected cells show very  
expression of the expected 55 kD full length protein, the transfected  
line expresses approximately 3-5 fold higher levels of this isoform  
15 (Figure 8B). Immunofluorescence analysis showed weak staining in  
the parental 32D cells whereas the transfected cells show very  
abundant staining on the surface with a capping pattern (Figure 8C,  
left panels). Surface expression of Evi27 was further shown by flow  
activated cell sorting analysis (Figure 8D). Clear cell surface  
staining was observed after analysis of live cells or fixed, but not  
20 permeabilized, transfected cells (data not shown). In all  
experiments the staining could be quenched by preincubation of the

antisera with Evi27 peptide (Figure 8C, right panels and Figure 8D), thus indicating the antiserum is specific for Evi27.

Murine T cell lymphoma EL-4 cells also express Evi27 on cell surface and the cell surface capping possibly indicates 5 polydimerization and receptor activation of Evi27 (Figure 9). In contrast, Evi27 shows different localization in murine AML cells. Myeloid leukemia cells B187 and B160 both show diffuse speckled staining pattern in the cytoplasm, whereas the B190 cells show a capping pattern similar to the T cell lymphoma EL-4 (Figures 10-11). 10 Moreover, abundant Evi27 protein was found in the cytoplasm, but not on the cell surface, of the B160 cells (Figure 11).

### **EXAMPLE 18**

15

#### Western blot analysis of Evi27 Protein Expression

Western blot analysis of a number of leukemia cell lines confirmed the Northern results and showed that many different Evi27 isoforms are expressed at the protein level (Figure 12). A 56 20 kD protein, which is the predicted size of the full length protein

containing the transmembrane and cytoplasmic domains, was expressed in most samples tested (Figure 12A). The EL4 and R1.1 T-cell lines and the WEHI 231 B-cell line also express a 24 kD protein, which is the predicted size of the truncated protein resulting from 5 intron incorporation and an 85 kD protein (Figure 12A). This protein is also expressed at low levels in the B190 cell line but not in the other the BXH2 leukemia cell lines tested.

Several cytokine receptors also produce soluble forms of the receptor by proteolytic cleavage of the membrane bound receptor. The cleavage sites are located near the plasma membrane in the extracellular domain of the receptor. Proteolytic cleavage of the Evi27 membrane receptor in this region is predicted to produce a 33 kD protein. A band of this size is also present in most samples tested (Figure 12A). Several unexpected sized Evi27 bands were also 15 detected on the Western blot. These protein bands can all be competed away by the addition of Evi27 peptide (Figure 12B), indicating that they contain authentic Evi27 protein sequences.

The origin of these protein bands is unknown but could result from the translation of Evi27 mRNA transcripts that have yet 20 to be sequenced or may be indicative of homo- or heteropolymer

formation. The expression of these protein bands is sometimes variable. For example, the 75 kD band is expressed at low or undetectable levels in the B160 and B187 cell lines. The B193 cell lines does not express the 150 kD and 127 kD bands, but does 5 expresses high levels of the 75 and 33 kD bands. The reason for this is not clear, but may reflect the differentiation state of the cell line. Consistent with this hypothesis, T- and B-cell lines express Evi27 protein bands that are not expressed in BXH2 myeloid cell lines (i.e., 24 and 85 kD bands).

Evi27 expression was also examined in human hematopoietic cells. Western blot analysis showed that MEG01 (megakaryocytic leukemia), K562 (chronic myelogenous leukemia) and HEL (erythrocytic leukemia) cell lines express the highest levels of Evi27 protein (Figure 13). Flow activated cell sorting analysis 15 indicated that there is high level of surface expression on THP-1 (monocytic leukemia) and K562 cells but not on HL-60 (promyelocytic leukemia) cells (Figure 14).

## Discussion

The studies described here show that retroviral integration at the *Evi27* locus in BXH2 murine myeloid leukemias results in the increased expression of a novel gene with homology to the *IL-17 receptor*. A number of cytokine receptors (i.e., *v-mpl* or *Tpor*, *Il6ra*, *Epor*, *Il9r*, *Csf1*, *Il2ra*, *Il4ra*, and *Ifngr2*) or their ligands (i.e., *Il6*, *Csf1*, *Il3*) are reported targets of retroviral integration or transduction in mouse leukemia/lymphomas making cytokines/cytokine receptors one of the largest and most important classes of leukemia genes (Ymer et al., 1985; Wendling et al., 1986; Penciolelli et al., 1987; Gisselbrecht et al., 1987; Sugita et al., 1990; Blankenstein et al., 1990; Souyri et al., 1990; Hino et al., 1991; Chretian et al., 1994; Flubacher et al., 1994; Li et al., 1999). The *Evi27*-encoded cytokine-related receptor is therefore an excellent candidate for a new leukemia disease gene.

The human *EVI27* gene was also cloned and mapped to chromosome 3p14-p21, in a region syntenic to the mouse gene. The human protein is 76% identical to the mouse protein at the amino acid level. This is somewhat higher than the recently described homology between the mouse and human IL-17 receptors, which are

69% identical at the amino acid level (Yao et al., 1997). This conservation suggests that *Evi27* receptor function is evolutionarily conserved between human and mouse.

Proviral integrations at *Evi27* are located about 6 kb upstream from the *IL-17 receptor*-related gene and result in increased gene expression. Viral integration at *Evi27* may thus induce disease simply by upregulating receptor expression. However, given the complex expression pattern observed for *Evi27*, it is also possible the viral integration induces disease by altering *Evi27* isoform expression. In the mouse, as many as six *Evi27* transcripts are detected on Northern blots. Two of the transcripts result from intron incorporation and are predicted to produce a truncated soluble form of the receptor lacking the transmembrane and cytoplasmic domains. Several cytokine receptors are known to produce soluble as well as membrane bound forms and it is now well documented that the soluble receptors can have both positive and negative effects on ligand signaling (for review see Heaney and Golde, 1996). The origin of the other *Evi27* transcripts has not been determined. It is thus possible that one or more of these uncharacterized messages encode sequences that are located

upstream of *Evi27* proviral integration sites at *Evi27*. If this is the case, then *Evi27* proviral integrations may prevent these messages from being expressed and this may have important disease consequences.

5 *IL-17r /Evi27* are unusual in that they have no homology with any protein in public databases, including other cytokine receptor proteins, and they have no recognizable motifs associated with intracellular signalling (Yao et al., 1995b). Many disease-related cytokine receptors involved in leukemogenesis contain kinase domains; however, it is not unprecedented to find receptors lacking kinase domains that are involved in disease. For example, the human *MASI* oncogene, which encodes a functional angiotensin receptor, is a G-protein coupled receptor that functions through phosphatidylinositol 4,5-bisphosphate hydrolysis (Young et al., 10 1986; Jackson et al., 1988). *Evi27* may thus identify a new disease 15 pathway.

At least seven different *Evi27* isoforms (i.e., 24, 33, 56, 47, 75, 127, and 150 kD in size) were also detected in BXH2 20 leukemia cell extracts by western analysis using an *Evi27*-specific antibody. All leukemia extracts expressed the 56 kD isoform (the

membrane bound receptor) as well as the 33 kD isoform (a postulated proteolytic cleavage containing the extracellular ligand-binding domain of the receptor). Expression of the other isoforms was variable among the extracts. One of seven cell extracts (B190) 5 expressed the 24 kD isoform (a putative truncated receptor resulting from intron incorporation), three extracts (B139, B160, and B187) express the 47 kD isoform, five extracts (B112, B132, B139, B190, B193) the 75 kD isoform, and six extracts (B112, B132, B139, B160, B187, B190) the 150 kD isoform. The origin of these 10 larger isoforms (i.e., oligomerization) or the reason for their variable expression (i.e. differentiation state of the cell) is presently unclear.

Only one BXH2 leukemia cell extract, B160, analyzed on Western blots is known to contain a proviral integration at *Evi27*. 15 The 56 kD isoform is overexpressed in B160 cells, consistent with Northern results showing that viral integration at *Evi27* results in increased *Evi27* expression. Surprisingly, the 56 kD isoform is also overexpressed in B187 cells, which are not known to carry a viral integration at *Evi27*. Perhaps, B187 cells harbor a viral integration 20 at *Evi27* that maps outside the region examined on Southern blots or

there are other mechanisms for upregulating expression of this isoform other than proviral integration. It is interesting to note that B187 cells, like B160 cells, also fail to express the 75 kD isoform. One intriguing possibility is that viral integration at *Evi27* blocks expression of this isoform.

5 *Evi27* expression is restricted in the hematopoietic cells. Northern analysis showed that *Evi27* is expressed in T cells and ESTs homologous to the mouse gene have been identified in CD4<sup>+</sup> T-cells. Likewise, the mouse preB-cell line WEHI231 expresses *Evi27* and ESTs homologous to *EVI27* have been identified in human germinal center B cells. No *Evi27* expression was seen in the late stage B-cell line 548, the Burkitt lymphoma cell line Raji, the murine erythroid line D1b, or the mast cell line P815. A complex pattern of expression was observed within the myeloid compartment. Variable expression 15 was seen in BXH2 leukemia cells, while little or no *Evi27* expression was seen in the M1 and 32D murine myeloid leukemia cell lines or in the monocytic leukemia cell line WEHI-3B. *Evi27* is expressed, however, in the chronic human myelogenous leukemia cell line K562, but not in the promyelocytic leukemia cell line HL-60. These 20 results suggest that *Evi27* expression may be tightly regulated during

myeloid cell differentiation and imply that *Evi27* may have an important function in controlling the growth and/or differentiation of hematopoietic cells. Proviral integration at *Evi27* may interfere with this function(s) and, in doing so, lead to myeloid disease.

5                   The *Evi27* subcellular protein distribution was also analyzed in various mouse hematopoietic cell lines. In the EL4 T-cell and WEHI231 B-cell lines, *Evi27* protein was largely found on the cell surface in a capping pattern. Interestingly, only one BXH2 leukemia cell line, B190, has a similar staining pattern. In the other BXH2 leukemia cell lines examined, including B160, which has a proviral integration at *Evi27*, *Evi27* protein is distributed throughout the cytoplasmic where it exhibits a punctate staining pattern. Western blot analysis shows that cells exhibiting the ER/Golgi staining pattern uniquely express the 24 kD *Evi27* isoform. It is possible that the 24  
10 kD isoform uniquely localizes to the ER/Golgi and somehow prevents the other *Evi27* isoforms from entering the cytoplasm. Alternatively, it is possible that a cofactor or heterodimeric partner required for transport from the ER/Golgi complex is differentially expressed. This hypothesis is strengthened by the fact that the 32D  
15 cell line transfected with the 56kD isoform still lacks the  
20

cytoplasmic distribution seen in B160 or B187. In support of this possible mechanism, the expression of beta-2-microglobulin is required for cell surface expression of MHC class I or class I-like molecules (Lamouse-Smith et al., 1993; Feder et al., 1998).

5 Additionally, the receptor-associated protein (RAP), a type of chaperone, is especially designed to assist in the biosynthesis and intracellular transport of endocytic receptors (Willnow, 1998) and band 3 (AE1 gene) plays a chaperone-like role required for the recruitment of Glycophorin A to the red blood cell plasma membrane (Hassoun et al., 1998). Finally, recent studies have shown that calnexin and Ig-alpha/Ig-beta interactions with membrane immunoglobulins are critical for the surface expression of the B cell antigen receptor of the IgM and IgD classes (Wu et al., 1997).

15 IL-17 (CTLA8) is a homodimeric cytokine of about 32 kD expressed exclusively from human memory T cells or mouse alpha beta TCR<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup> thymocytes (Rouvier et al., 1993; Yao et al 1995a; Yao et al., 1995b; Kennedy et al., 1996). In contrast with the tightly controlled expression of the ligand, the IL-17 receptor is 20 ubiquitously distributed but more abundant in spleen and kidney

(Yao et al., 1995b). Although devoid of direct effects on cells of hematopoietic origin, IL-17 induces the secretion of IL-6, IL-8, PGE2, MCP1 and G-CSF by adherent cells like fibroblasts, keratinocytes, epithelial and endothelial cells (Yao et al., 1995a; Yao et al., 1995b; 5 Fossiez et al., 1996). When cultured in the presence of IL-17, fibroblasts can sustain the proliferation of CD34<sup>+</sup> human progenitors and their preferential differentiation into neutrophils (Fossiez et al., 1996). Adenovirus-mediated transfer of murine IL-17 cDNA into liver has also been shown to induce a transient, but dramatic granulopoiesis *in vivo*, except in IL-6-deficient mice (Schwarzenberger et al., 1998).

The Evi27 protein is a member of the IL-17 receptor family. Two new members of the IL-17 cytokine family have recently been identified and these studies have demonstrated that 15 IL-17B and IL-17C do not bind the IL-17 receptor extracellular domain, indicating that IL-17B and IL-17C are likely to bind unique, yet uncharacterized receptors (Li et al., 2000). In a survey of cytokine induction, IL-17B and IL-17C stimulate the release of TNF- $\alpha$  and IL-1 $\beta$  from the monocytic leukemia cell line THP-1 (Li et al., 2000). RT-PCR analysis has shown that IL-17B is expressed by both

the B160 leukemia and the stromal cell on which it depends. It is speculated that Evi27 may represent the receptor for IL-17B or IL017C. Based on these data a model for Evi27 in myeloid leukemia development is proposed. Terminal differentiation of 5 myelomonocytic precursor cells likely result in the down regulation of Evi27 expression. However, proviral insertions at Evi27 result in constitutive expression of the receptor. Binding of IL-17B/C to the Evi27 receptor would trigger the release of TNF- $\alpha$  and the IL-1 $\beta$  by the leukemic cells. The TNF- $\alpha$  and IL-1 $\beta$  would in turn provoke the production of multilineage hematopoietic growth factors, adhesion molecules, and inflammatory cytokines by stromal cells (Bagby, 1994). These stromal cell derived factors then support the growth and survival of the leukemia cell and may account for the absolute dependence of the B160 leukemia on the stromal feeder layer for 15 growth and survival.

The human homologue of *Evi27* may also be involved in human disease. *EVI27* maps to chromosome 3p21, a region consistently deleted in a variety of human cancers. Loss of 3p heterozygosity is also frequently observed in renal cell carcinoma, 20 lung cancer and breast cancer and analysis of 3p allele loss in renal

cell cancer has localized a candidate tumor suppressor gene to 3p21 (van den Berg et al., 1997). These results are consistent with the hypothesis that chromosome 3p encodes a number of tumor suppressor genes. Given that *EVI27* maps to 3p21 and is expressed 5 at high levels in normal human kidney, it will be interesting to determine whether this gene is affected by 3p21 mutations in renal cell carcinoma. *EVI27* also may be a human myeloid leukemia disease gene. Recurrent treatment-related chromosome 3p21 breaks are frequently observed in myelodysplastic syndrome and 10 acute myeloid leukemia patients (Shi et al., 1996), and 3p21 is the most frequently deleted region in human CML (Johansson et al., 1997). Future studies will be aimed at determining whether *EVI27* is a human myeloid leukemia disease gene.

An Evi27 ligand, IL-17E, that induces activation of NF- $\kappa$ B 15 and stimulates production of the proinflammatory chemokine IL-8 was identified recently. Together with the restricted expression of Evi27 disclosed herein, it is likely that Evi27 mediates the secretion of proinflammatory cytokines such as IL-8 and plays important role in the developmental and/or disease processes of hematopoietic 20 cells. Hence, modulating the expression of Evi27 at the RNA or

protein level may be exploited for use in the treatment of diseases such as cancer or autoimmune diseases. A number of methods can be used to modulate Evi27 expression, e.g. by anti-sense oligonucleotides, small molecules that bind to the receptor, 5 modified IL-17E ligand that may stimulate or repress the activity of the Evi27 receptor, and the use of soluble form of the Evi27 receptor.

The following references were cited herein:

10 Bagby (1994). *The Molecular Basis of Blood Diseases.* Stamatoyannopoulos G, Nienhuis A.W., Majerus P.W. and Varmus H. (eds). W.B. Saunders Press: Philadelphia, p. 71-106.

Baumbach et al., (1988). *J. Virol.*, **62**, 3151-5

Bedigian et al., (1984). *J. Virol.*, **51**, 586-594.

15 Benton et al., (1977). *Science*, **196**, 180-2.

Blankenstein et al., (1990). *J. Exp. Med.*, **171**, 965-70

Buchburg et al., (1990) *Mol. Cell. Biol.*, **10**, 4658-4666.

Chretien et al., (1994). *Blood*, **83**, 1813-1821

Copeland et al., (1993). *Science*, **262**, 57-66.

20 Copeland NG, Jenkins NA 1999. Myeloid leukemia: disease genes

and mouse models. In *Animal Models of Cancer Predisposition Syndromes* (eds Hiai, H. & Hino, O.) 53-63 (Karger, Basel, 1999).

Feder et al., (1998). *Proc Natl Acad Sci U S A.*, **95**, 1472-7.

Flubacher et al., (1994) *J. Virol.*, **68**, 7709-16

5 Fossiez et al., (1996). *J. Exp. Med.*, **183**, 2593-603.

Gilbert et al., (1993). *J. Virol.*, **67**, 2083-90.

Hassoun et al., (1998). *Blood* **91**, 2146-51.

Heaney et al., (1996). *Blood*, **87**, 847-57

Hino et al., (1991). *Mol. Cell. Biol.*, **11**, 5527-33.

10 Jackson et al., (1988). *Nature* **335**, 437-40

Jenkins et al., (1982). *J. Virol.*, **42**, 379-388.

Johansson et al., (1997). *Leukemia*, **11**, 1207-13.

Kennedy et al., (1996) *J. Interferon Cytokine Res.*, **16**, 611-617.

Lamouse-Smith et al., (1993). *J. Immunol.*, **15**, 6283-90.

15 Largaespada et al., (1995). *J. Virol.*, **69**, 5095-5102.

Li et al., (1999). *Nat. Genet.*, **23**, 348-353.

Li et al., (2000). *Proc. Natl. Acad. Sci. USA*, **97**, 773-778.

Liao et al., (1997). *Oncogene*, **14**, 1023-9.

Look AT. (1997). *Science*, **278**, 1059-64.

20 Lupas, et al., (1991). *Science*, **252**, 1162-1164.

Morishita et al., (1988). *Cell*, **54**, 831-40

Nakai et al., (1992). *Genomics*, **14**, 897-911.

Nakamura, et al., (1996a) *Nat. Genet.* **12**, 149-153.

Nakamura, et al., (1996b). *Nat. Genet.*, **12**, 154-158.

5 Ogawa et al., (1996). *Oncogene*, **13**, 183-91.

Roberts et al., (1998). *Hum. Mol. Genet.*, **7**, 1169-78

Rouvier et al., (1993). *J Immunol* **150**, 5445-56.

Sambrook et al., *Molecular Cloning, A Laboratory Manual 2nd edn.*  
(Cold Spring Harbor, Laboratory Press New York, 1989).

10 Schwarzenberger et al., (1998). *J. Immunol.*, **161**, 6383-9.

Shaughnessy et al., (1999). *Oncogene*, **18**, 2069-84.

Shi et al., (1996). *Cytogenet. Cell Genet.*, **74**, 295-9

Sugita et al., T. (1990). *J. Exp. Med.*, **171**, 2001-9.

Viskochil et al., (1990). *Cell*, **62**, 187-92.

15 van den Berg et al., (1997) *Genes Chromosomes Cancer*, **19**, 228-32.

Willnow TE. (1998). *Biol. Chem.*, **379**, 1025-31.

Wu Y, Pun C, Hozumi N. (1997). *Immunol.*, **158**, 2762-70.

Yao et al., (1995a). *Immunity*, **3**, 811-821.

Yao et al., (1995b). *J. Immunol.*, **155**, 5483-6

20 Yao et al., (1997). *Cytokine*, **9**, 794-800

Young et al., (1986). *Cell*, **45**, 711-9.

Ymer et al., (1985). *Nature*, **317**, 255-8.

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to 5 which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will appreciate readily that the 10 present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of 15 preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.